Olivier Brandicourt | |
|---|---|
 Brandicourt in November 2013 | |
| Born | 13 February 1956 Casablanca, Morocco |
| Nationality | French |
| Occupation | Business executive |
Olivier Brandicourt (born 13 February 1956) is a French business executive and physician, and the former chief executive officer of Sanofi.
Brandicourt studied medicine in Paris and specialized in infectious diseases and tropical medicine. He spent eight years with the Institute of Infectious and Tropical Diseases of the Pitié-Salpêtrière Hospital in Paris, where he focused on malaria research in West and Central Africa. [1] Prior to that, he spent two years in the Republic of the Congo as a doctor. [2]
He holds an advanced degree in Cellular and Immunological Pathophysiology from Paris Descartes University and a master's degree in biology from University of Paris XII.
Brandicourt joined Pfizer in 2000, after its acquisition of Warner-Lambert/Parke-Davis, where he started his career, first in Medical Affairs and later in Marketing and Management. He spent 12 years at Pfizer Inc. where he held several senior positions across a range of disciplines, including President and General Manager of the Global Specialty Care and Primary Care businesses, and later as president and General Manager of the Primary Care Business Unit. [3] [4] He served as a member of the executive leadership team of Pfizer Inc. and oversaw the introduction of the cholesterol treatment Lipitor. [2] [5] In 2007, he was the supervisor of the failed launch of the Exubera. [6]
From 2013 to 2015, he was chief executive officer and chairman of the board of management of Bayer HealthCare AG, where he was responsible for leading the company's healthcare portfolio globally, encompassing pharmaceuticals, consumer care, animal health and medical care businesses. [7]
In February 2015, Olivier Brandicourt was appointed as the chief executive officer of Sanofi. [2] [8] [9] His golden handshake of US$4.5 million upon taking on the appointment was criticized by French Ministers Stéphane Le Foll and Ségolène Royal. [10]
In November 2015, Sanofi announced its 2020 Strategic Plan that implies reshaping its activities into 3 portfolios: Diabetes, cardiovascular, and vaccines. [11] In May 2016, Olivier Brandicourt announced a reshuffle in the company's management, in line with the 2020 Strategic Plan. [12]
In January 2017, Sanofi completed an asset swap of its animal health business, Merial, for Boehringer's consumer healthcare business, CHC. Subsequently, Sanofi launched a fifth Global Business Unit for Consumer Health Care. [13]
Pharmaceutical Research and Manufacturers of America, formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States. Founded in 1958, PhRMA lobbies on behalf of pharmaceutical companies. PhRMA is headquartered in Washington, DC.
The minister of health is the minister of the Crown in the Canadian Cabinet who is responsible for overseeing health-focused government agencies including Health Canada and the Public Health Agency of Canada, as well as enforcing the Canada Health Act, the law governing Canada's universal health care system.
Elias Zerhouni is an Algerian-born American scientist, radiologist and biomedical engineer.
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.
Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois. It had approximately 19,000 employees. Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems. Hospira's products are used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. It was formerly the hospital products division of Abbott Laboratories. On September 3, 2015, Hospira was acquired by Pfizer, who subsequently sold off the medical devices portion of Hospira to ICU Medical.
Boehringer Ingelheim Animal Health is a multinational animal health company, formed in January 2017 when Merial was acquired by Boehringer Ingelheim and merged with Boehringer Ingelheim's existing animal health assets.
The ethics involved within pharmaceutical sales is built from the organizational ethics, which is a matter of system compliance, accountability and culture. Organizational ethics are used when developing the marketing and sales strategy to both the public and the healthcare profession of the strategy. Organizational ethics are best demonstrated through acts of fairness, compassion, integrity, honor, and responsibility.
The National Health Council (NHC) is a nonprofit association of health organizations.
Network for Excellence in Health Innovation (NEHI), formerly New England Healthcare Institute is a member-based, non-partisan research and policy organization.
Olivier Jean Bohuon is a French businessman. He was the chief executive (CEO) of Smith & Nephew plc, a British multinational medical equipment manufacturing company.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Lise Kingo is a Danish businesswoman who currently serves as Independent Board Director at Danone, Sanofi and Covestro. Kingo is also a member of the Advisory Board for Humanitarian and Development Aid at the Novo Nordisk Foundation.
The Verband Forschender Arzneimittelhersteller (vfa) or Association of Research-Based Pharmaceutical Companies, is the trade group of 43 pharmaceutical companies in Germany which are global players, representing more than two-thirds of the German pharmaceutical market, with nearly 80,000 employees in Germany.
Albert Bourla is a Greek-American veterinarian and the chairman and chief executive officer of Pfizer, an American pharmaceutical company. He joined the company in 1993 and has held several executive roles across Pfizer's divisions. Prior to becoming chief executive officer, Bourla served as chief operating officer.
Joaquin Duato is a Spanish-American business executive. Duato is a dual citizen of Spain and the United States. He is the chairman and chief executive officer (CEO) of Johnson & Johnson, an American multinational conglomerate. He is the eighth person to serve as CEO of Johnson & Johnson since it became a publicly-traded company in 1944.
